Skip to main content
IMVT
NASDAQ Life Sciences

Immunovant Reports Strong IMVT-1402 RA Trial Results, Discontinues Batoclimab, and Provides Q4/FY26 Financials

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$32.66
Mkt Cap
$5.351B
52W Low
$13.79
52W High
$30.16
52W Position info
137% above low
Off High info
at 52W high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

IMVT has more than doubled off its 52-week low of $13.79.

Summary

Immunovant reported strong preliminary clinical trial results for its lead asset, IMVT-1402, in rheumatoid arthritis, while discontinuing its batoclimab program and detailing Q4 and full-year 2026 financial results.


Key Events · Product Development and Regulatory · IMVT

  • Strong IMVT-1402 RA Trial Results

    Preliminary Week 16 results for IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) showed high response rates: 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70. Further updates are expected in the second half of calendar year 2026.

  • Batoclimab Program Discontinued

    Following failed Phase 3 trials for thyroid eye disease, Immunovant has discontinued all development of batoclimab, incurring $39.0 million in contractual costs, to focus entirely on IMVT-1402.

  • Solid Cash Position and Runway

    The company reported $902.1 million in cash and cash equivalents as of March 31, 2026, providing financial runway through the potential commercial launch of IMVT-1402 in Graves' Disease.

  • Q4 and Full-Year 2026 Financials

    Immunovant reported a Q4 2026 net loss of $147.9 million ($0.73 per share) and a full-year 2026 net loss of $505.6 million ($2.77 per share), with increased R&D expenses driven by IMVT-1402 development and batoclimab discontinuation costs.


Analysis · IMVT · Life Sciences

Immunovant announced highly positive preliminary Week 16 results for its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis (D2T RA), showing strong response rates (72.7% ACR20, 54.5% ACR50, 35.8% ACR70). This success for their lead asset is a major positive for the company's pipeline. Concurrently, Immunovant discontinued development of batoclimab across all indications after its Phase 3 thyroid eye disease trials failed to meet primary endpoints, incurring $39.0 million in contractual costs. This strategic pivot allows the company to fully focus resources on IMVT-1402. The company also reported a cash position of $902.1 million, providing runway through the potential commercial launch of IMVT-1402 in Graves' Disease. The stock is currently trading above its previous 52-week high, reflecting strong market confidence in the IMVT-1402 program.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMVT was trading at $32.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.79 to $30.16. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMVT - Latest Insights

IMVT
Nov 09, 2026, 7:20 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.20
Real-time Price: $33.17 info
Change: -$2.03 (-6%) info
Market Cap: $6.864B info
IMVT
Nov 09, 2026, 7:09 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.85
Real-time Price: $33.17 info
Change: -$2.68 (-7%) info
Market Cap: $6.864B info
IMVT
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.10
Real-time Price: $33.17 info
Change: +$5.07 (+18%) info
Market Cap: $6.864B info
IMVT
Nov 09, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $28.10
Real-time Price: $33.17 info
Change: +$5.07 (+18%) info
Market Cap: $6.864B info
IMVT
Sep 23, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $36.20
Real-time Price: $33.17 info
Change: -$3.03 (-8%) info
Market Cap: $6.864B info